3-(4-Hydroxyphenyl)-4-(2-methylpropyl)oxolane-2,5-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-(4-Hydroxyphenyl)-4-(2-methylpropyl)oxolane-2,5-dione
• 英文别名: 3-(4-hydroxyphenyl)-4-(2-methylpropyl)oxolane-2,5-dione
• 化学式: C₁₄H₁₆O₄
• 分子量: 248.27
• InChiKey: KZLFRVFXQHOHPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• NOVEL COMPOUNDS FROM ANTRODIA CAMPHORATA
  申请人：Kuo Yueh-Hsiung

  公开号：US20100130584A1

  公开（公告）日：2010-05-27

  Compounds isolated from the fruiting body of A. camphorata in a solid culture or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds or pharmaceutically acceptable salts thereof.
• USE OF NOVEL COMPOUNDS FROM FRUITING BODY OF ANTRODIA CAMPHORATA FOR TREATING AN INFLAMMATORY DISORDER
  申请人：Kuo Yueh-Hsiung

  公开号：US20120149753A1

  公开（公告）日：2012-06-14

  Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of A. camphorata in a solid culture. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds and pharmaceutical compositions including the compounds or pharmaceutically acceptable salts thereof.
• PHARMACEUTICAL COMPOSITION FOR TREATING CANCER IN AN INDIVIDUAL SUBJECT SUFFERING CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170042912A1

  公开（公告）日：2017-02-16

  A pharmaceutical composition for treating cancer in an individual, comprising at least a pharmaceutically effective amount of a novel target HCC reversal signal substance, and a pharmaceutically acceptable ingredient comprising a vehicle, a carrier, a diluent or an excipient; in which the ratio among each component of the pharmaceutical composition may be adjustable depending on the type of cancer; wherein the novel target HCC reversal signal substance comprises at least one selected from the group consisting of antroquinonol (AQL), antrocinnamonin A (ACA), antroquinonol B (AQB), antroquinonol D (AQD), dehydroeburicoic acid (DEA), dehydrosulphurenic acid (DSA), zhankuic acid A (ZAA), zhankuic acid C (ZAC), antcin K (ANK), antcin C (ANC), and a mixture thereof.
• PHARMACEUTICAL COMPOSITION FOR TREATING COLORECTAL CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170189417A1

  公开（公告）日：2017-07-06

  The present invention provides a pharmaceutical composition for treating colorectal cancer in a subject in need thereof, which comprises a first agent comprising at least a Zhankuic acid D (ZhAD); and a second agent comprising at least an Antroquinonol B (AnQB); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of Antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of colorectal cancer or to prevent or to reduce the risk of a colorectal cancer metastasizing, compared to administration of the first agent or the second agent alone.
• PHARMACEUTICAL COMPOSITION FOR TREATING LUNG CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170189418A1

  公开（公告）日：2017-07-06

  The present invention provides a pharmaceutical composition for treating lung cancer in a subject in need thereof, which comprises a first agent comprising at least a dehydroeburicoic acid (DeEA); and a second agent comprising at least an Anctin K(AnK); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of Antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of lung cancer or to prevent or to reduce the risk of a lung cancer metastasizing, compared to administration of the first agent or the second agent alone.